Build Your Comparison

Side-by-side financial analysis
OMI logo
OMI
MCK logo
MCK
KO logo
KO
JPM logo
JPM
CAH logo
CAH
Try popular comparisons:

Stock Comparison

OMI vs MCK vs KO vs JPM vs CAH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
OMI
Owens & Minor, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$171M
5Y Perf.-70.6%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$90.23B
5Y Perf.+441.8%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$341.71B
5Y Perf.+67.4%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$908.57B
5Y Perf.+225.2%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$52.19B
5Y Perf.+311.7%

OMI vs MCK vs KO vs JPM vs CAH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
OMI logoOMI
MCK logoMCK
KO logoKO
JPM logoJPM
CAH logoCAH
IndustryMedical - DistributionMedical - DistributionBeverages - Non-AlcoholicBanks - DiversifiedMedical - Distribution
Market Cap$171M$90.23B$341.71B$908.57B$52.19B
Revenue (TTM)$2.76B$403.43B$49.28B$280.33B$250.55B
Net Income (TTM)$-1.10B$4.76B$13.70B$57.05B$1.56B
Gross Margin3.6%61.7%60.0%3.7%
Operating Margin1.0%1.6%29.3%25.9%0.9%
Forward P/E2.3x17.0x24.3x14.6x20.6x
Total Debt$320M$8.61B$45.49B$942.38B$9.35B
Cash & Equiv.$282M$3.98B$10.27B$343.34B$3.87B

OMI vs MCK vs KO vs JPM vs CAHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

OMI
MCK
KO
JPM
CAH
StockJun 20Feb 26Return
Owens & Minor, Inc. (OMI)10029.4-70.6%
McKesson Corporation (MCK)100541.8+441.8%
The Coca-Cola Compa… (KO)100167.4+67.4%
JPMorgan Chase & Co. (JPM)100325.2+225.2%
Cardinal Health, In… (CAH)100411.7+311.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: OMI vs MCK vs KO vs JPM vs CAH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. JPMorgan Chase & Co. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. MCK and CAH also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
OMI
Owens & Minor, Inc.
The Value Angle

Among these 5 stocks, OMI doesn't own a clear edge in any measured category.

Best for: healthcare exposure
MCK
McKesson Corporation
The Growth Play

MCK ranks third and is worth considering specifically for growth exposure.

  • Rev growth 12.4%, EPS growth 49.2%, 3Y rev CAGR 13.4%
  • 12.4% revenue growth vs OMI's -74.2%
Best for: growth exposure
KO
The Coca-Cola Company
The Quality Compounder

KO carries the broadest edge in this set and is the clearest fit for quality and dividends.

  • 27.8% margin vs OMI's -39.8%
  • 2.6% yield, 56-year raise streak, vs MCK's 0.4%, (1 stock pays no dividend)
  • 13.1% ROA vs OMI's -44.9%, ROIC 15.8% vs 1.8%
Best for: quality and dividends
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.

  • Dividend streak 15 yrs, beta 0.87, yield 1.8%
  • 481.2% 10Y total return vs MCK's 328.4%
  • Lower volatility, beta 0.87, current ratio 0.52x
  • PEG 0.83 vs KO's 2.17
Best for: income & stability and long-term compounding
CAH
Cardinal Health, Inc.
The Momentum Pick

CAH is the clearest fit if your priority is momentum.

  • +35.3% vs OMI's -70.0%
Best for: momentum
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK12.4% revenue growth vs OMI's -74.2%
ValueJPM logoJPMLower P/E (14.6x vs 20.6x)
Quality / MarginsKO logoKO27.8% margin vs OMI's -39.8%
Stability / SafetyJPM logoJPMBeta 0.87 vs OMI's 1.41
DividendsKO logoKO2.6% yield, 56-year raise streak, vs MCK's 0.4%, (1 stock pays no dividend)
Momentum (1Y)CAH logoCAH+35.3% vs OMI's -70.0%
Efficiency (ROA)KO logoKO13.1% ROA vs OMI's -44.9%, ROIC 15.8% vs 1.8%

OMI vs MCK vs KO vs JPM vs CAH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

OMIOwens & Minor, Inc.
FY 2025
Diabetes Product
56.9%$783M
Product and Service, Other
20.9%$288M
Wound Care
13.7%$189M
Urology
8.4%$116M
MCKMcKesson Corporation
FY 2026
North American Pharmaceutical Segment
83.4%$336.7B
Oncology And Multispecialty Segment
12.0%$48.4B
Medical-Surgical Solutions Segment
2.9%$11.5B
Prescription Technology Solutions Segment
1.4%$5.8B
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
0.3%$1.0B
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B

OMI vs MCK vs KO vs JPM vs CAH — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGJPM

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 4 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 146.1x OMI's $2.8B. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to OMI's -39.8%. On growth, KO holds the edge at +12.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricOMI logoOMIOwens & Minor, In…MCK logoMCKMcKesson Corporat…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …CAH logoCAHCardinal Health, …
RevenueTrailing 12 months$2.8B$403.4B$49.3B$280.3B$250.5B
EBITDAEarnings before interest/tax$277M$7.1B$15.5B$81.4B$3.2B
Net IncomeAfter-tax profit-$1.1B$4.8B$13.7B$57.0B$1.6B
Free Cash FlowCash after capex-$353M$5.9B$12.6B$100.9B$4.4B
Gross MarginGross profit ÷ Revenue+3.6%+61.7%+60.0%+3.7%
Operating MarginEBIT ÷ Revenue+1.0%+1.6%+29.3%+25.9%+0.9%
Net MarginNet income ÷ Revenue-39.8%+1.2%+27.8%+20.4%+0.6%
FCF MarginFCF ÷ Revenue-12.8%+1.5%+25.5%+36.0%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year-146.3%+6.0%+12.1%+11.0%
EPS Growth (YoY)Latest quarter vs prior year+4.5%+37.0%+18.2%+16.0%-19.5%
KO leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

OMI leads this category, winning 4 of 7 comparable metrics.

At 16.2x trailing earnings, JPM trades at a 53% valuation discount to CAH's 34.4x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs KO's 2.34x — a lower PEG means you pay less per unit of expected earnings growth.

MetricOMI logoOMIOwens & Minor, In…MCK logoMCKMcKesson Corporat…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …CAH logoCAHCardinal Health, …
Market CapShares × price$171M$90.2B$341.7B$908.6B$52.2B
Enterprise ValueMkt cap + debt − cash$209M$94.9B$376.9B$1.51T$57.7B
Trailing P/EPrice ÷ TTM EPS-0.16x19.56x26.12x16.22x34.38x
Forward P/EPrice ÷ next-FY EPS est.2.31x16.96x24.27x14.60x20.60x
PEG RatioP/E ÷ EPS growth rate2.34x0.92x
EV / EBITDAEnterprise value multiple1.70x13.21x25.45x18.52x18.81x
Price / SalesMarket cap ÷ Revenue0.06x0.22x7.13x3.25x0.23x
Price / BookPrice ÷ Book value/share9.99x2.51x
Price / FCFMarket cap ÷ FCF15.78x64.52x9.01x28.21x
OMI leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 4 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-21 for OMI. KO carries lower financial leverage with a 1.33x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs OMI's 2/9, reflecting strong financial health.

MetricOMI logoOMIOwens & Minor, In…MCK logoMCKMcKesson Corporat…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …CAH logoCAHCardinal Health, …
ROE (TTM)Return on equity-21.1%+41.1%+15.9%
ROA (TTM)Return on assets-44.9%+5.7%+13.1%+1.3%+2.8%
ROICReturn on invested capital+1.8%+2.5%+15.8%+4.5%+33.8%
ROCEReturn on capital employed+1.3%+44.8%+17.3%+8.9%+19.2%
Piotroski ScoreFundamental quality 0–927756
Debt / EquityFinancial leverage1.33x2.60x
Net DebtTotal debt minus cash$38M$4.6B$35.2B$599.0B$5.5B
Cash & Equiv.Liquid assets$282M$4.0B$10.3B$343.3B$3.9B
Total DebtShort + long-term debt$320M$8.6B$45.5B$942.4B$9.3B
Interest CoverageEBIT ÷ Interest expense-0.12x51.78x10.70x0.74x6.38x
KO leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CAH leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in CAH five years ago would be worth $41,353 today (with dividends reinvested), compared to $514 for OMI. Over the past 12 months, CAH leads with a +35.3% total return vs OMI's -70.0%. The 3-year compound annual growth rate (CAGR) favors CAH at 35.7% vs OMI's -50.9% — a key indicator of consistent wealth creation.

MetricOMI logoOMIOwens & Minor, In…MCK logoMCKMcKesson Corporat…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …CAH logoCAHCardinal Health, …
YTD ReturnYear-to-date-3.4%-8.6%+16.4%+0.8%+8.3%
1-Year ReturnPast 12 months-70.0%+3.4%+17.7%+20.9%+35.3%
3-Year ReturnCumulative with dividends-88.2%+85.0%+39.3%+138.8%+149.7%
5-Year ReturnCumulative with dividends-94.9%+312.8%+65.3%+135.5%+313.5%
10-Year ReturnCumulative with dividends-87.3%+328.4%+115.0%+481.2%+215.4%
CAGR (3Y)Annualised 3-year return-50.9%+22.8%+11.7%+33.7%+35.7%
CAH leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — KO and JPM each lead in 1 of 2 comparable metrics.

KO is the less volatile stock with a -0.23 beta — it tends to amplify market swings less than OMI's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 96.2% from its 52-week high vs OMI's 23.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricOMI logoOMIOwens & Minor, In…MCK logoMCKMcKesson Corporat…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …CAH logoCAHCardinal Health, …
Beta (5Y)Sensitivity to S&P 5001.41x-0.11x-0.23x0.87x-0.05x
52-Week HighHighest price in past year$9.55$999.00$84.04$338.09$233.60
52-Week LowLowest price in past year$1.84$637.00$65.35$269.72$137.75
% of 52W HighCurrent price vs 52-week peak+23.5%+75.1%+94.5%+96.2%+94.9%
RSI (14)Momentum oscillator 0–10046.551.849.272.175.4
Avg Volume (50D)Average daily shares traded690K906K13.6M7.4M2.0M
Evenly matched — KO and JPM each lead in 1 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: OMI as "Hold", MCK as "Buy", KO as "Buy", JPM as "Buy", CAH as "Buy". Consensus price targets imply 596.4% upside for OMI (target: $16) vs 4.5% for JPM (target: $340). For income investors, KO offers the higher dividend yield at 2.56% vs MCK's 0.41%.

MetricOMI logoOMIOwens & Minor, In…MCK logoMCKMcKesson Corporat…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …CAH logoCAHCardinal Health, …
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuyBuy
Price TargetConsensus 12-month target$15.60$994.86$86.13$339.75$253.38
# AnalystsCovering analysts1031486133
Dividend YieldAnnual dividend ÷ price+0.4%+2.6%+1.8%+0.9%
Dividend StreakConsecutive years of raises018561540
Dividend / ShareAnnual DPS$3.07$2.04$5.95$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.3%+0.2%+3.8%+1.5%
KO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

KO leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). OMI leads in 1 (Valuation Metrics). 1 tied.

Best OverallThe Coca-Cola Company (KO)Leads 3 of 6 categories
Loading custom metrics...

OMI vs MCK vs KO vs JPM vs CAH: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is OMI or MCK or KO or JPM or CAH a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 12.

4% revenue growth year-over-year, versus -74. 2% for Owens & Minor, Inc. (OMI). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — OMI or MCK or KO or JPM or CAH?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 2x versus Cardinal Health, Inc. at 34. 4x. On forward P/E, Owens & Minor, Inc. is actually cheaper at 2. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 83x versus The Coca-Cola Company's 2. 17x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — OMI or MCK or KO or JPM or CAH?

Over the past 5 years, Cardinal Health, Inc.

(CAH) delivered a total return of +313. 5%, compared to -94. 9% for Owens & Minor, Inc. (OMI). Over 10 years, the gap is even starker: JPM returned +481. 2% versus OMI's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — OMI or MCK or KO or JPM or CAH?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

23β versus Owens & Minor, Inc. 's 1. 41β — meaning OMI is approximately -705% more volatile than KO relative to the S&P 500. On balance sheet safety, The Coca-Cola Company (KO) carries a lower debt/equity ratio of 133% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — OMI or MCK or KO or JPM or CAH?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 12.

4% versus -74. 2% for Owens & Minor, Inc. (OMI). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -201. 1% for Owens & Minor, Inc.. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — OMI or MCK or KO or JPM or CAH?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -39. 8% for Owens & Minor, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus 1. 0% for OMI. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is OMI or MCK or KO or JPM or CAH more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 83x versus The Coca-Cola Company's 2. 17x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Owens & Minor, Inc. (OMI) trades at 2. 3x forward P/E versus 24. 3x for The Coca-Cola Company — 22. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OMI: 596. 4% to $15. 60.

08

Which pays a better dividend — OMI or MCK or KO or JPM or CAH?

In this comparison, KO (2.

6% yield), JPM (1. 8% yield), CAH (0. 9% yield), MCK (0. 4% yield) pay a dividend. OMI does not pay a meaningful dividend and should not be held primarily for income.

09

Is OMI or MCK or KO or JPM or CAH better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

23), 2. 6% yield, +115. 0% 10Y return). Both have compounded well over 10 years (KO: +115. 0%, OMI: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between OMI and MCK and KO and JPM and CAH?

These companies operate in different sectors (OMI (Healthcare) and MCK (Healthcare) and KO (Consumer Defensive) and JPM (Financial Services) and CAH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OMI is a small-cap quality compounder stock; MCK is a mid-cap quality compounder stock; KO is a large-cap quality compounder stock; JPM is a large-cap deep-value stock; CAH is a mid-cap quality compounder stock. KO, JPM, CAH pay a dividend while OMI, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.